NEW YORK (360Dx) – Bio-Rad Laboratories said on Tuesday that it has entered into an agreement that gives it commercialization rights to Visia Imaging's second-generation immunofluorescence slide processing and reading platform for the evaluation of autoimmune diseases.

Laboratories frequently employ immunofluorescence slides as a first step in screening for numerous autoimmune diseases, including systemic lupus erythematosus, Bio-Rad said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.